Safety and efficacy of Empagliflozin in Pakistani Muslim patients with type 2 diabetes (SAFE-PAK); a randomized clinical trial

Table 2 Comparison of adverse events between Empagliflozin and standard care groups during the study period

Adverse Events	Group A	Group B	P-value
Adverse Events	(n = 108)	(n = 101)	P-value
Hypoglycemic events
Yes	6(5.6)	10(9.9)	0.238
No	102(94.4)	91(90.1)	0.238
Dehydration
Yes	3 (2.78)	3 (2.97)	0.934
No	105(97.2)	98(97.0)	0.934
Hypotension
Yes	1 (0.93)	1 (0.99)	0.962
No	107(99.1)	100(99.0)	0.962
UTI
Positive	6 (5.56)	7 (6.93)	0.681
Negative	102(94.4)	94(93.1)	0.681
Fungal Infection
Yes	–	2 (1.98)	0.142
No	108(100)	99(98.0)	0.142
Treatment Discontinuation due to AE*	2 (1.6)	2 (1.7)	0.908

Group A-Empagliflozin; Group B-Standard Care
Values are presented in n (%). Chi-squared test was applied to determine the P-value considered significance at < 0.05 *AE Adverse events

ISSN: 1472-6823